Hikma Pharmaceuticals PLC (LON:HIK – Get Free Report) passed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of GBX 1,448.89 and traded as high as GBX 1,569. Hikma Pharmaceuticals shares last traded at GBX 1,509.61, with a volume of 42,938,281 shares trading hands.
Analysts Set New Price Targets
A number of equities analysts have recently commented on the stock. Berenberg Bank reissued a “buy” rating and issued a GBX 1,800 price target on shares of Hikma Pharmaceuticals in a research report on Tuesday, April 28th. Citigroup restated a “buy” rating on shares of Hikma Pharmaceuticals in a report on Thursday. Jefferies Financial Group boosted their price objective on Hikma Pharmaceuticals from GBX 1,850 to GBX 1,870 and gave the stock a “buy” rating in a research report on Tuesday, May 5th. Finally, Deutsche Bank Aktiengesellschaft reiterated a “buy” rating and set a GBX 195 price target on shares of Hikma Pharmaceuticals in a report on Monday, June 22nd. Six equities research analysts have rated the stock with a Buy rating, According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of GBX 1,687.
View Our Latest Stock Report on Hikma Pharmaceuticals
Hikma Pharmaceuticals Trading Up 0.3%
About Hikma Pharmaceuticals
At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly. We are a trusted, reliable partner and dependable source of over 820+ (as of Feb 2026) high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe.
Recommended Stories
- Five stocks we like better than Hikma Pharmaceuticals
- Why Abbott Laboratories Stock Is Suddenly Winning Back Wall Street
- Revving Up Returns: Big Banks Race Through the Rate Plateau
- Why Uber’s Biggest Deal Yet Could Unlock Its Next Growth Phase
- Why Microsoft Is Playing a Different AI Game Than Big Tech—and Cash Flow Is the Test
Receive News & Ratings for Hikma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
